Article Figures & Tables
Tables
- Box 2: Characteristics of cases of salivary duct adenocarcinoma treated with androgen deprivation therapy
Author No. of cases Age, yr (median) Androgen deprivation therapy Response Locati et al. (6) 7 68 Bicalutamide + LHRH analogue 1 CR
2 PR
1 SDJaspers et al. (5) 10 66 9 bicalutamide, 1 bicalutamide + LHRH analogue 2 PR
3 SD
5 PDSoper et al. (3) 1 87 Bicalutamide + LHRH analogue + RT CR Yamamoto et al. (11) 1 66 Bicalutamide CR Agbarya et al. (1) 1 57 Bicalutamide CR Urban et al. (4) 1 45 Abiraterone, prednisone and LHRH analogue CR Our patient (Box 1) 1 72 Bicalutamide + LHRH analogue PR Note: CR = complete response, LHRH = luteinizing hormone–releasing hormone, PD = progressive disease, PR = partial response, RT = radiation therapy, SD = stable disease.